GoAI
Get started
Vyome Holdings, Inc. logo

Vyome Holdings, Inc.

HIND

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.25

−$0.03 · -1.32%

Aug 21, 4:00 PM ET

Pre-market

$2.25

$0.00 · 0.00%

Aug 24, 4:06 AM ET

HIND company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

41

Fair Value

Momentum

32

Weakening

Sentiment

49

Mixed

Risk resilience

27

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $2.25

52-week range

Current $2.25

Open
$2.21
Previous close
$2.28
Volume
4.39K
Market cap
15.79M USD
50-day average
$2.1768
+3.36% above average
200-day average
$2.8486
-21.01% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.08×
P/B (TTM)
2.61×
P/S (TTM)
121.73×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
46.50%
Operating margin
-3250.25%
Net margin
-8716.77%

Financial health

Debt / equity
0×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends392%-918%-2227%-3537%Gross margin, FY2021: 61.38%Gross margin, FY2022: 60.52%Gross margin, FY2023: 63.93%Gross margin, FY2024: 63.17%Gross margin, FY2025: 64.68%Operating margin, FY2021: -425.60%Operating margin, FY2022: -240.91%Operating margin, FY2023: -168.69%Operating margin, FY2024: -96.53%Operating margin, FY2025: -859.22%Net margin, FY2021: -464.31%Net margin, FY2022: -411.16%Net margin, FY2023: -131.22%Net margin, FY2024: -89.06%Net margin, FY2025: -3209.75%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 61.38%. Gross margin FY2022 60.52%. Gross margin FY2023 63.93%. Gross margin FY2024 63.17%. Gross margin FY2025 64.68%. Operating margin FY2021 -425.60%. Operating margin FY2022 -240.91%. Operating margin FY2023 -168.69%. Operating margin FY2024 -96.53%. Operating margin FY2025 -859.22%. Net margin FY2021 -464.31%. Net margin FY2022 -411.16%. Net margin FY2023 -131.22%. Net margin FY2024 -89.06%. Net margin FY2025 -3209.75%.

Income trends

Revenue

319.71K USD-96.01%

Operating income

−2.75M USD+64.45%

Net income

−10.26M USD-43.93%
Income trends across reported periods21.27M USD−9.42M USD−40.12M USD−70.82M USDRevenue, FY2021: 13.6M USDRevenue, FY2022: 11.24M USDRevenue, FY2023: 8.68M USDRevenue, FY2024: 8.01M USDRevenue, FY2025: 319.71K USDOperating income, FY2021: −57.88M USDOperating income, FY2022: −27.08M USDOperating income, FY2023: −14.64M USDOperating income, FY2024: −7.73M USDOperating income, FY2025: −2.75M USDNet income, FY2021: −63.15M USDNet income, FY2022: −46.21M USDNet income, FY2023: −11.39M USDNet income, FY2024: −7.13M USDNet income, FY2025: −10.26M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 13.6M USD. Revenue FY2022 11.24M USD. Revenue FY2023 8.68M USD. Revenue FY2024 8.01M USD. Revenue FY2025 319.71K USD. Operating income FY2021 −57.88M USD. Operating income FY2022 −27.08M USD. Operating income FY2023 −14.64M USD. Operating income FY2024 −7.73M USD. Operating income FY2025 −2.75M USD. Net income FY2021 −63.15M USD. Net income FY2022 −46.21M USD. Net income FY2023 −11.39M USD. Net income FY2024 −7.13M USD. Net income FY2025 −10.26M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue319.71K USD8.01M USD8.68M USD11.24M USD13.6M USD
Cost of goods sold112.93K USD2.95M USD3.13M USD4.44M USD5.25M USD
Gross profit206.79K USD5.06M USD5.55M USD6.8M USD8.35M USD
Research and development588.26K USD1.8M USD2.32M USD2.54M USD2.37M USD
Selling, general, and administrative2.37M USD9.92M USD17.87M USD31.34M USD33.21M USD
Operating expenses2.95M USD12.79M USD20.19M USD33.88M USD66.23M USD
Interest income—14K USD26K USD——
Interest expense146.64K USD——113K USD832K USD
Depreciation and amortization11.99K USD22K USD154K USD2.15M USD1.97M USD
Operating income−2.75M USD−7.73M USD−14.64M USD−27.08M USD−57.88M USD
Net income−10.26M USD−7.13M USD−11.39M USD−46.21M USD−63.15M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
6 beats, 1 miss, 2 met estimates
Average EPS surprise
-255.75%
9 comparable reports
Latest EPS result
-0.1
Estimate -0.19 · Beat by 47.37%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates52.98-111.35-275.67-440Q2 '25BeatQ2 '25No estimateQ3 '25No estimateQ4 '25MissQ1 '26MetQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual -47.25, estimate -406, surprise +88.36%, Beat. Q2 2025, reported May 21, 2025: actual 18.98, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual -2.25, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual -3.12, estimate -0.11, surprise -2736.36%, Miss. Q1 2026, reported Mar 26, 2026: actual -0.47, estimate -0.47, surprise 0.00%, Met estimate. Q2 2026, reported May 19, 2026: actual -0.15, estimate -0.15, surprise 0.00%, Met estimate. Q3 2026, reported Aug 12, 2026: actual -0.1, estimate -0.19, surprise +47.37%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.42M2.29M1.16M20.49KQ2 '25MissQ2 '25No estimateQ3 '25No estimateQ4 '25MetQ1 '26MetQ2 '26MetQ3 '26MetQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual 1.81M USD, estimate 3.17M USD, surprise -43.11%, Miss. Q2 2025, reported May 21, 2025: actual 1.11M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 249K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 34.63K USD, estimate 34.63K USD, surprise 0.00%, Met estimate. Q1 2026, reported Mar 26, 2026: actual 36.55K USD, estimate 36.55K USD, surprise 0.00%, Met estimate. Q2 2026, reported May 19, 2026: actual 31.59K USD, estimate 31.59K USD, surprise 0.00%, Met estimate. Q3 2026, reported Aug 12, 2026: actual 26.96K USD, estimate 26.96K USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 13, 2026: actual —, estimate 24.11K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy133%
Hold267%
Sell00%
Strong sell00%

HIND peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding HIND

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
20.11K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research HIND

research.disclaimer